Propanc Biopharma plans Phase 1b cancer trial, posts $18.9M net loss

Go back to Propanc Biopharma plans Phase 1b cancer trial, posts $18.9M net loss
(NASDAQ: PPCB) Delayed: 0.26 -0.01 (3.7%)
Previous Close $0.27    52 Week High $ 
Open $0.28    52 Week Low $ 
Day High $0.28    P/E N/A 
Day Low $0.25    EPS $ 
Volume 89,274